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Variation in cystic fibrosis (CF) phenotypes, including lung disease severity, age of onset of persistent Pseudomonas aeruginosa
(P. aeruginosa) lung infection, and presence of meconium ileus (MI), has been partially explained by genome-wide association studies
(GWASs). It is not expected that GWASs alone are sufficiently powered to uncover all heritable traits associated with CF phenotypic
diversity. Therefore, we utilized gene expression association from lymphoblastoid cells lines from 754 p.Phe508del CF-affected ho-
mozygous individuals to identify genes and pathways. LPAR6, a G protein coupled receptor, associated with lung disease severity
(false discovery rate q value ¼ 0.0006). Additional pathway analyses, utilizing a stringent permutation-based approach, identified
unique signals for all three phenotypes. Pathways associated with lung disease severity were annotated in three broad categories:
(1) endomembrane function, containing p.Phe508del processing genes, providing evidence of the importance of p.Phe508del pro-
cessing to explain lung phenotype variation; (2) HLA class I genes, extending previous GWAS findings in the HLA region; and (3)
endoplasmic reticulum stress response genes. Expression pathways associated with lung disease were concordant for some endosome
and HLA pathways, with pathways identified using GWAS associations from 1,978 CF-affected individuals. Pathways associated with
age of onset of persistent P. aeruginosa infection were enriched for HLA class II genes, and those associated with MI were related to
oxidative phosphorylation. Formal testing demonstrated that genes showing differential expression associated with lung disease
severity were enriched for heritable genetic variation and expression quantitative traits. Gene expression provided a powerful tool
to identify unrecognized heritable variation, complementing ongoing GWASs in this rare disease.The genetic architecture of phenotypic variability in cystic
fibrosis (CF [MIM 219700]) is beginning to be defined,1–5
but GWASs for CF are limited by numbers of subjects
compared to common diseases, where tens of thousands
of subjects have been used to identify pathophysiologi-
cally relevant pathways.6–8 Studies of gene expression pro-
vide an alternative approach to identify genemodifiers.9–11
Based upon the established utility of gene expression
studies in lymphoblastoid cell lines (LCLs),12–14 global
gene expression was measured from LCLs of a highly phe-
notyped CF cohort previously used for GWAS analysis1 and
analyzed for association with three distinct CF phe-
notypes: lung disease severity, age of onset of persistent
Pseudomonas aeruginosa (P. aeruginosa) pulmonary infec-
tion, and meconium ileus (MI [MIM 614665]) at birth
(Table 1; Figure S1).
Affymetrix Human Exon (1.0 ST) microarray data were
collected from RNA isolated from 754 LCLs selected from1Marsico Lung Institute/UNC CF Research Center, School of Medicine, Univer
ment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
North Carolina State University, Raleigh, NC 27695, USA; 4Department of Biost
USA; 5State Key Laboratory of Medical Genomics, Shanghai Institute of Hemat
of Medicine, Shanghai 200025, China; 6Department of Biostatistics, Harvard U
perial College London, London SW7 2AZ, UK; 8McKusick-Nathans Institute of
School of Medicine, Baltimore, MD 21287, USA; 9Department of Pediatrics, Sc
USA; 10Program in Genetics and Genome Biology, The Hospital for Sick Childr
ON M5G 1X8, Canada; 11Program in Child Health Evaluative Sciences, The H
Public Health, University of Toronto, ONM5G 1X8, Canada; 12Department of B
13These authors contributed equally to this work
*Correspondence: wanda_o’neal@med.unc.edu
http://dx.doi.org/10.1016/j.ajhg.2014.12.022. 2015 by The American Societ
318 The American Journal of Human Genetics 96, 318–328, Februarya cohort of 1,137 samples from CFTR (MIM 602421)
p.Phe508del European individuals homozygous for the
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affected individuals were originally obtained for the Ge-
netic Modifiers in CF Lung Disease Study where a GWAS
had been performed1 (Figure S2). Considerable efforts
were taken to ensure that high-quality microarray data
were utilized and that interpretation would not be
confused by known effect of SNPs on probe hybridization
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Table 1. Characteristics of Subject Population for Phenotypes
Study
Group
Consortium Lung Phenotype (Primary Analysis)a
Age of Onset of Persistent
Pseudomonas aeruginosa
Meconium
Ileus (MI)
Size of
Population
Age at Enrollment
(year)
No. Males
(%)
No. Europeanb
(%)
Persistent Culture
Positivec (%)
Age of Onset
(year)
Presence of
MId (%)Mean 5 SD Range Mean 5 SD Range
Severe 317 16.5 5 4.6 8–25 157 (49.5) 317 (100) 208 of 222 (93.7) 5.2 5 4.3 0.6–19 52 of 301 (17.3)
Mild 437 28.0 5 9.9 15–58 221 (50.5) 437 (100) 203 of 233 (87.1) 16.8 5 10.3 0.6–57 54 of 405 (13.3)e
Total 754 455 706
aSubjects were classified as having either severe or mild lung disease, as defined by the quantitative Consortium lung phenotype (KNoRMA) value of<0.3 or>0.3,
respectively.18
bBased on self-identified ancestry and principal components analysis via SNP genotypes.
cData were obtained at the encounter level (each clinic visit) from the Cystic Fibrosis Foundation (CFF) Patient Registry. Persistent is defined as cultured
P. aeruginosa in respiratory cultures 2 years in a row, or 2 out of 3 years, unless subjects had at least 5 consecutive years of negative cultures after meeting minimal
criteria (2 out of 3 years of positive cultures). Subjects who were above age 7 needed to have a negative culture before the first positive culture to be included into
the analysis.28 There were 14 severe and 30 mild subjects who were negative for P. aeruginosa at last culture.
dSubjects were confirmed to have MI if a diagnosis at birth was supported by source documents, such as the original surgical or medical report, detailed clinical or
admissions note, or verbal confirmation from the subject or the parent with documentation of an abdominal scar. Subjects were removed from the analysis if MI
could not be confirmed or if the diagnosis was unclear or unknown.
ePresence of MI was 17.6% (36 of 205) for subjects enrolled at 15–25 years of age.analysis. The study was approved by the biomedical insti-
tutional review board of the University of North Carolina
and the institutional review board of each participating
institution. CF-affected individuals and their parents (if
they were a minor) provided written informed consent.
Linear regression was utilized to establish association of
gene expression with phenotypes. Gene expression values
meeting a minimal threshold of expression above 6.03 (on
the Affymetrix RMA standard log2 scale) were utilized,
based on the 95th percentile of mean ‘‘expression’’ in fe-
males for genes on the Y chromosome, because this
threshold was considered to reliably represent true signal
above background. All genes meeting this criterion
(12,033 out of 17,868 annotated genes; 67.3%) were
included in the linear regression analysis, including genes
whose probes overlaid SNPs with high minor allele fre-
quency (MAF), but these genes were ‘‘flagged’’ so that
potentially important interpretive issues could be consid-
ered later. The covariates used for all analyses are listed in
Table S1. The genotype PCs used as covariates were calcu-
lated with Eigenstrat15 and available genotype data from
the previously conducted GWASs.1 The surrogate variables
of gene expression data were calculated with the ‘‘sva’’
package in Bioconductor in R.16 The Q-Q plots for all three
phenotypes suggested that the covariates included were
appropriate to control for population stratification or tech-
nical factors that could potentially lead to false positives
(Figure S4).
The expression of lysophosphatidic acid receptor 6
(LPAR6 [MIM 278150]) achieved transcriptome-wide sig-
nificance for association with lung disease (false discovery
rate q value ¼ 0.0006, p value ¼ 5.35 3 108), using both
standard and alternative probe annotation (ANNMAP,
formerly known as X:MAP),17 with higher levels of
LPAR6 being associated with worse lung function. Array-
based LPAR6 expression was technically validated byThe AmericTaqMan quantitative real-time PCR (p < 0.0001 between
36 low-expressing and 40 high-expressing LCL samples
from CF-affected individuals). CHMP4C (p ¼ 1.05 3 105
[MIM 610899]), SSBP2 (p ¼ 2.60 3 105 [MIM 607389]),
and P2RX4 (p ¼ 8.03 3 105 [MIM 600846]) were sugges-
tive for association (Table S2; Figure S5; see Table S5 for
complete list).
As explicitly accounted for by the Consortium lung
phenotype,18 older surviving CF-affected individuals
have milder lung disease, reflecting high mortality in CF
(Table 1). To investigate a possible relationship between
age and gene expression in the CF cohort, but unrelated
to CF lung disease, we examined three large external
studies of LCL gene expression. These included a child-
hood asthma (MIM 600807) cohort evaluated on the Affy-
metrix platform,19 available data from the Cholesterol
and Pharmacogenomics (CAP) trial (available on Array-
Express),20 and the Multiple Tissue Human Expression
Resource (MuTHER) study.21 No correspondence emerged
between differentially expressed genes for the Consortium
lung phenotype and those associated with age in these
three non-CF populations (Figure S6), although LPAR6
was nominally associated with age (not corrected for mul-
tiple comparison) in older women (age ~59 years) in the
MuTHER study.21 Consequently, we conclude that the as-
sociations seen in our study reflect CF lung disease severity
and not aging.
Rigorous ‘‘pathway’’ (gene set) analysis was conducted
via a permutation-based approach (Significance Analysis
of Function and Expression; SAFE), which accounts for
gene expression correlation structures and allows testing
of both standard and custom-derived pathways.22 Pathway
analysis was conducted by SAFE in R (v.3.0) and annota-
tion databases (available at Bioconductor) hugene10stpro-
beset.db and GO.db (Gene Ontology annotation maps).
Multiple pathways with q values < 0.15 were found toan Journal of Human Genetics 96, 318–328, February 5, 2015 319
Table 2. Gene Expression Pathways Significantly Associated with Consortium Lung Phenotype
Pathway Genes Statistics
ID Name Number [a Yb Trendc p Valued q Valuee
Genes with Gene-Level p Value
< 0.05 (Ordered by p Value)f
GO Cellular Component Pathways
0001673 male germ cell nucleus 14 0 14 down 0.0001 0.0164 TNP1; REC8; TCFL5
0012507 ER to Golgi transport vesicle
membrane
25 23 2 up 0.0003 0.0481 HLA-E; MCFD2; TMED7; HLA-F
0043073 germ cell nucleus 17 1 16 down 0.0004 0.0442 TNP1; REC8; TCFL5
0042470;
0048770
melanosome; pigment granule 78 52 26 up 0.0007 0.0582 SLC3A2; TPP1; CTSD; ANXA2; STOM;
HSPA5; BSG
0030134 ER to Golgi transport vesicle 29 25 4 up 0.0011 0.0737 HLA-E; MCFD2; TMED7; HLA-F
0030176 integral to endoplasmic reticulum
membrane
85 64 21 up 0.0024 0.1181 TTC35; HLA-E; EDEM1; TAP1; SELS;
HLA-F; HSPA5; MMGT1
0031301 integral to organelle membrane 171 113 58 up 0.0026 0.1181 TTC35; HLA-E; EDEM1; TAP1; SELS;
ST6GALNAC6; HLA-F; A4GALT; ARMCX3;
P2RX7; LARGE; HSPA5; MMGT1
0000421 autophagic vacuole membrane 13 11 2 up 0.0028 0.1181 WIPI1; ATG9A
0031227 intrinsic to endoplasmic reticulum
membrane
95 70 25 up 0.0031 0.1181 TTC35; HLA-E; EDEM1; TAP1; SELS;
HLA-F; HSPA5; MMGT1
0031300 intrinsic to organelle membrane 184 121 63 up 0.0036 0.1231 TTC35; HLA-E; EDEM1; TAP1; SELS;
ST6GALNAC6; HLA-F; A4GALT; ARMCX3;
P2RX7; LARGE; HSPA5; MMGT1
0030658 transport vesicle membrane 49 33 16 up 0.0039 0.1231 HLA-E; MCFD2; TMED7; HLA-F; NCALD
GO Biological Process Pathways
0006518 peptide metabolic process 64 46 18 up 0.0001 0.0837 GSTK1; DNPEP; PSEN2; TPP1
0072384 organelle transport along microtubule 24 21 3 up 0.0001 0.0837 PRKCZ; COPG
0006925 inflammatory cell apoptotic process 10 10 0 up 0.0003 0.1107 none
0006944 cellular membrane fusion 61 42 19 up 0.0003 0.1107 CD9; PLDN; ANXA2; BET1
0007030 golgi organization 38 28 10 up 0.0003 0.1107 GCC2; BHLHA15; GOLGB1; PLK3;
COG1; TMED2
0043603 cellular amide metabolic process 101 65 36 up 0.0003 0.1107 GSTK1; DNPEP; PSEN2; TPP1; PRKCD
0034067 protein localization to Golgi apparatus 14 13 1 up 0.0004 0.1166 GOLGA4; GCC2; ATG9A
0045684 positive regulation of epidermis
development
11 10 1 up 0.0004 0.1166 none
GO Molecular Function Pathways
0050839 cell adhesion molecule binding 33 15 18 two sided 0.0004 0.1181 P2RX4; MLLT4; CD1D;g CTNNA1; PVRL1g
0042287 MHC protein binding 15 9 6 two sided 0.0006 0.1191 TAP1; LAG3; MARCH8
MSigDB Pathways
ATAAGCT.MIR.21 81 45 36 two sided 0.0001 0.0387 BAHD1; BTBD3;g C5orf41; STK40; UBR3;
NF2;g SSFA2; JAG1; PPARA; PELI1; RHOB;
CREBL2
V.HMGIY_Q6 158 70 88 two sided 0.0006 0.1499 ZNF675;g LMO4; TNFSF11;g PLAGL2;
POLD3;g SLC7A1; UBE2E2;g TAZ; UBR3;
MRC2;g TNFSF4; IKZF2g
MetaMiner Cystic Fibrosis Specific Pathwaysh
cholesterol and sphingolipids
transport/recycling to plasma
membrane in lung (normal and CF)
14 9 5 two sided 0.0036 0.0597 ABCG1g
normal wtCFTR traffic/sorting
endosome formation
14 11 3 up 0.0052 0.0621 none
(Continued on next page)
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Table 2. Continued
Pathway Genes Statistics
ID Name Number [a Yb Trendc p Valued q Valuee
Genes with Gene-Level p Value
< 0.05 (Ordered by p Value)f
F508-CFTR traffic/ER-to-Golgi in CF;
Normal wtCFTR traffic/ER-to-Golgi
22 20 2 up 0.0075 0.0621 COPG; COPZ2
mucin expression in CF via TLRs,
EGFR signaling pathways
48 34 14 up 0.0116 0.0770 JUN; PRKCD
PFAM Pathways
00035 double-stranded RNA binding motif 17 2 15 down 0.0001 0.0135 STRBP; STAU2
07716 basic region leucine zipper 11 7 4 two sided 0.0002 0.0276 DDIT3; CREBL2; CEBPB
03953 tubulin C-terminal domain 15 2 13 down 0.0009 0.0804 TUBB2B
CF Relevant Custom Pathways
ER stress response 169 127 42 up 0.0005 0.0106 DNAJB9; EDEM1; CISD2; TANK; DDIT3;
SERP1; FDPS; LONP1; NANS; SSR4; JUN;
GADD45A; LY9; PGM3; HSPA5; ARF4;
IER3IP1; BTG2; CEBPB; CNIH; MANF;
PDIA6
XBP1 target genes 13 10 3 two sided 0.0079 0.1165 DNAJB9; EDEM1; SERP1; PDIA6
HLA-Specific Pathways
class I 3 3 0 up 0.0221 0.0261 HLA-E; HLA-F
class II 8 7 1 up 0.0868 0.0580 none
class I and class II 11 10 1 up 0.0299 0.0261 HLA-E; HLA-F
Pathways limited to those with R10 but %200 genes. SAFE analysis utilized 10,000 permutations to establish significance thresholds. CF Relevant Custom
Pathways developed primarily as described for mice46 using human gene counterparts (Table S8).
aNumber of genes in pathway with increased expression.
bNumber of genes in pathway with decreased expression.
cUp (increased) or down (decreased) differential expression of genes in the pathways associated with milder lung disease. Two-sided indicates pathways that
contained both increased and decreased differentially expressed genes that contributed significantly to the signal.
dDetermined by 10,000 permutations in the SAFE package.22
eBenjamini-Hochberg false-discovery for pathways testing within each pathway set; q values < 0.15 were included.
fSee Table S6 (tab A) for the inclusive list of genes for these pathways; ‘‘none’’ indicates that no individual genes within the pathway had a p value less than 0.05;
see Table S5 for gene MIM numbers.
gFor the two-sided ‘‘Trend,’’ these genes have a ‘‘down’’ trend.
hMetaMiner CF Specific Pathways represent a version of Thomson Reuters’ (formerly GeneGo) MetaDiscovery suite that is enriched with content specific for cystic
fibrosis.associate with lung disease severity (Table 2; Table S6,
tab A). Of the 35 pathways listed (Table 2), 16 were related
to the endomembrane system for synthesis and post-trans-
lational modification of membrane proteins (membranes,
vesicle traffic, and Golgi/endoplasmic reticulum [ER])
and two pathways were related to ER stress response,
which also could represent a subset of endomembrane pro-
cesses. Of the 11 Gene Ontology (GO) Cellular Compo-
nent pathways, 7 contained HLA class I genes, and
custom-derived pathways consisting exclusively of HLA
genes were also highly significant (Table 2). Importantly,
although the HLA genes clearly contributed to the signifi-
cance of the endomembrane pathways, these same path-
ways also contained TTC35 (Table 2 [MIM 607722]) and
TMEM85 (Table S6, tab A; p value ¼ 0.06), which are the
human homologs of yeast genes EMC2 and EMC4, respec-
tively, known to modulate yeast homolog of p.Phe508del
processing.23 MetaMiner Cystic Fibrosis Specific Pathways
not containing HLA genes also supported association with
p.Phe508del processing (Table 2). We conclude that threeThe Americimportant pathophysiological signals have emerged: HLA
class I, p.Phe508del processing, and the ER stress response.
The significance of the miR21 (miRNA-21 [MIM 611020])
pathway is also relevant given the expanding role of this
microRNA (miRNA) in pulmonary biology.24 Most path-
ways trended in the ‘‘up’’ direction (increased expression
of genes in the pathways associated with milder lung dis-
ease), with two pathways (annotated to germ cell nuclei)
trending ‘‘down.’’
We hypothesized that the expression pathways would be
concordant with pathways identified with GWAS asso-
ciations of genotype data with lung disease severity. We
used a gene- andpathway-testing approach25 (GeneSetScan
v.0.01) applied to GWAS data from the previously
genotyped cohort of US and Canadian CF-affected individ-
uals1 (n¼1,978, including theCF-affected individuals from
the expression study) to provide resampling-based multi-
ple-comparison corrected p values for the numbers of
pathways tested. Three significant (corrected p < 0.05)
pathways were identified (Table 3; Table S6, tab B).an Journal of Human Genetics 96, 318–328, February 5, 2015 321
Table 3. GWAS Data Pathways Significantly Associated with Consortium Lung Phenotype
ID Name Genes (n)
Corrected
p Valuea Z Score Genes with Gene-Level p Value < 0.05 (Ordered by p Value)
Analyses Included All Available Pathwaysb
KEGG Pathways
05320 autoimmune thyroid disease 49 0.002 4.469 HLA-DRB1; HLA-DQA1; HLA-DRA; IFNA13; IFNA8; IFNA2; IFNA16;
IFNA17; IFNA6; IFNA10; IFNA1; IFNA7; IFNA14; IFNA4; HLA-DQB1;
IFNA5; IFNA21; HLA-E; HLA-DQA2
04672 intestinal immune network
for IgA production
45 0.018 3.822 HLA-DRB1; HLA-DQA1; HLA-DRA; TNFRSF17; HLA-DQB1; CXCL12;
HLA-DQA2
MSigDB Pathways
TGCAAAC.MIR-452 106 0.049 3.676 SAV1; TRPS1; ATL1; ZIC1; NIN; SH3BGRL; SYN3; XPNPEP1; XPO4; RAB8B
Analyses Confined to Pathways Significant for Differential Expressionc
GO Cellular Component Pathways
0030134 ER to Golgi transport vesicle 39 0.001 4.271 HLA-DRB1; HLA-DQA1; HLA-DRA; MCFD2; HLA-DQB1; SEC24B; HLA-E;
SREBF1; HLA-DQA2
0012507 ER to Golgi transport vesicle
membrane
33 0.001 4.218 HLA-DRB1; HLA-DQA1; HLA-DRA; MCFD2; HLA-DQB1; SEC24B; HLA-E;
SREBF1; HLA-DQA2
CF Relevant Custom Pathways
ER stress response 248 0.029 1.962 FGFR4; HMOX1; UBE2L6; TAX1BP1; CREB3; ARL1; UBXN4; RNF5; ATF6B;
USO1; GADD45A; NIPSNAP1; XBP1; AMFR; TOR1A; SREBF1; PSMB2
HLA-Specific Pathways
class I 7 0.0382 1.842 HLA-E
class II 11 0.0254 2.285 HLA-DRB1; HLA-DQA1; HLA-DRA; HLA-DQB1; HLA-DQA2
class I and class II 18 0.0101 2.771 HLA-DRB1; HLA-DQA1; HLA-DRA; HLA-DQB1; HLA-E; HLA-DQA2
Default parameters with 1,000 resamples were used, and pathways were limited to those that containedR10 but%200 genes. GeneSetScan utilizes a mapping
of SNPs to genes based upon a reference panel from HapMap release 23a and mapped genes to pathways based upon a March 2011 release of GO and KEGG
pathways. The number of permutations for the HLA-specific analysis was increased to 10,000 to improve precision for this relevant group of genes. See Table S6
(tab B) for the inclusive list of genes for these pathways. See Table S5 for gene MIM numbers.
aMultiple comparison corrected p.
bGene level p values calculated using family-wise (all SNPs, genes, and pathways tested) as provided by GeneSetScan.
cPathways listed in Table 2 were evaluated for association to genotype. Pathways are listed in this table if p value < 0.05.Two of these pathways (KEGG05320, autoimmune thy-
roid disease; and KEGG04672, intestinal immune network
for IgA production) were enriched in HLA class II genes,
congruent with GWAS signal previously reported at chro-
mosome 6p.1 A third pathway indicated a role for
miR452 (miRNA-452), a miRNA associated with epithelial
development26 and alveolar macrophage function.27 Addi-
tional analysis of the GWAS data confined specifically
to pathways significant for differential gene expression
(Table 2) identified two overlapping ER-to-Golgi HLA-
enriched pathways and a pathway containing ER stress
response genes (Table 3; Table S6, tab B). Thus, concor-
dance between GWAS and gene expression was observed
in biologically relevant pathways. However, the top-
ranked genes within the pathways were different between
GWAS and expression datasets; thus, the concordance
might represent distinct genetic signals.
Analyses of expression associated with age of onset of
persistent P. aeruginosa lung infection and MI phenotypes
were also performed on subsets of the CF cohort (Table 1;
Table S1; Figures S1B and S1C). Significant pathways322 The American Journal of Human Genetics 96, 318–328, Februarywere also associated with each of these two phenotypes
(Table 4; Table S3; Tables S5 and S6, tabs C and D). After ad-
justing for lung disease severity, which correlates with
older age of onset of persistent P. aeruginosa infection in
CF-affected individuals withmilder lung disease28 (Table 1;
Figure S1B), multiple pathways were associated with age of
onset of persistent P. aeruginosa (Table 4). KEGG and GO
pathways associated with P. aeruginosa were enriched for
pathways containing HLA class II genes (5 of 12 total listed
pathways; Table 4; Figure 1; Table S4) rather than the class I
genes that were prevalent in expression association with
lung disease (Table 2; Figure 1; Table S4).
As seen in association with lung disease severity (Table 2),
GO Cellular Component and MetaMiner CF Specific Path-
ways annotated to endomembrane function (lysosomes,
vacuolar, and endosomes) were associated with age of onset
of persistent P. aeruginosa infection. Additionally, congruent
with the lung function associations, pathways consist-
ing exclusively of HLA genes were significant for the
P. aeruginosa phenotype (Table 4 bottom, HLA-Specific Path-
ways), but the HLA class II genes contributed to a larger5, 2015
Table 4. Gene Expression Pathways Significantly Associated with Age of Onset of Persistent Pseudomonas aeruginosa
Pathway Genes Statistics
ID Name Number [a Yb Trendc p Valued q Valuee
Genes with Gene-Level p Value < 0.05
(Ordered by p Value)f
KEGG Pathways
05213 endometrial cancer 50 36 14 up 0.0014 0.1479 PIK3R3; CTNNA1; GSK3B; CTNNB1; LEF1; CASP9
05323 rheumatoid arthritis 50 38 12 up 0.0024 0.1479 TNF; HLA-DMA; HLA-DPA1; HLA-DOB; ATP6V0E1;
HLA-DMB; CD80; IL15; CSF1; HLA-DRA; HLA-DOA
04940 type I diabetes mellitus 24 20 4 up 0.0026 0.1479 TNF; HLA-E; HLA-DMA; HLA-DPA1; LTA; HLA-DOB;
HLA-DMB; CD80; FAS; HLA-DRA; HLA-DOA
GO Molecular Function Pathways
0004620 phospholipase activity 46 34 12 up 0.0003 0.0857 PLA2G12A; SMPD2; LIPH; MGLL; SMPD1
0001614;
0016502
purinergic nucleotide receptor
activity; nucleotide receptor
activity
19 6 13 two sided 0.0007 0.1392 GPR15; P2RY1; GPR109A; GPR18g
GO Biological Process Pathways
0001556 oocyte maturation 11 4 7 two sided 0.0002 0.1391 PTK2B; BRCA2;g CDC25B;g RPS6KA2; TRIP13;g
INSL3;g ANG;g CCNB1g
0006865 amino acid transport 79 43 36 two sided 0.0002 0.1391 TNF; CLN8; PRKCD; CACNB4; ARL6IP5; SLC25A26;
PSEN1; CPT2; ACACB;g SLC38A10;g SLC1A1;
SLC25A32;g SLC9A3R1;g CPT1A;g SERINC1
0007163 establishment or maintenance
of cell polarity
85 51 34 two sided 0.0002 0.1391 ARHGEF2; ARHGEF11; PTK2B; NDC80;g CKAP5;g
DLG1; CAP1; CYTH1; CTNNA1; ERBB2IP; DST;
ACTR3; GNB2L1; NCKAP1L; CENPA;g ZW10;g
CLASP1; CYTH3; GSK3B; SCRIB;g MAP4; PRKCZ;
CDK5RAP2;g RAB11FIP2;g EZR
GO Cellular Component Pathways
0000794 condensed nuclear chromosome 54 10 44 down 0.0004 0.0617 SMC1A; CHEK1; BUB1B; PLK1; BUB1; NDC80;
TOP2A; AURKB; NCAPD3; INCENP; CENPA;
H2AFX; NEK2; SUV39H1; SMC3; RAD21;
CCNB1; ADD3
0005765 lysosomal membrane 109 78 31 up 0.0008 0.1064 CD74; CD1D; HLA-DPA1; HLA-DMA; OSTM1;
HLA-DOB; VPS39; HLA-DMB; ARL8B; PSEN1;
TMEM63A; ARL8A; RAB7A; HLA-DRA; HLA-DOA;
AP1S1; AP1S3; LAMP3
0044437 vacuolar part 184 129 55 up 0.0010 0.1064 CD74; CD1D; HLA-DPA1; HLA-DMA; ATG16L1;
OSTM1; DAPK2; TPP1; GLB1; HLA-DOB; VPS39;
GM2A; HLA-DMB; ARL8B; PSEN1; TMEM63A;
ARL8A; VPS41; IDUA; RAB7A; WIPI2; CTSF;
HLA-DRA; HLA-DOA; AP1S1; SMPD1; AP1S3;
HEXA; LAMP3
0005774 vacuolar membrane 141 99 42 up 0.0015 0.1211 CD74; CD1D; HLA-DPA1; HLA-DMA; ATG16L1;
OSTM1; HLA-DOB; VPS39; HLA-DMB; ARL8B;
PSEN1; TMEM63A; ARL8A; VPS41; RAB7A; WIPI2;
HLA-DRA; HLA-DOA; AP1S1; AP1S3; LAMP3
MetaMiner Cystic Fibrosis Specific Pathwaysh
normal wtCFTR traffic/sorting
endosome formation
14 13 1 up 0.0022 0.0352 STX12; VPS45; RAB7A
F508-CFTR traffic/sorting
endosome formation in CF
20 16 4 up 0.0042 0.0455 STX12; STAM2; VPS45; RAB7A
PFAM Pathways
00017 SH2 domain 79 60 19 up 0.0003 0.0275 PIK3R3; LYN; FER; TXK; BLK; HCK; SOCS6; INPP5D;
LCP2; SH3BP2; FGR
00788 Ras association (RalGDS/AF-6)
domain
26 22 4 up 0.0003 0.0275 RGL2; RASSF5; MYO9B; RGL1; ARAP2
00225 kinesin motor domain 31 10 21 two sided 0.0003 0.0418 KIF23;g KIF4A;g KIF14;g KIF11;g KIF15;g KIF18A;g
KIF20B;g KIF22;g KIF3A; KIF2A
(Continued on next page)
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Table 4. Continued
Pathway Genes Statistics
ID Name Number [a Yb Trendc p Valued q Valuee
Genes with Gene-Level p Value < 0.05
(Ordered by p Value)f
HLA-Specific Pathways
class I 3 3 0 up 0.0960 0.0645 HLA-E
class II 8 8 0 up 0.0117 0.0105 HLA-DPA1; HLA-DMA; HLA-DOB; HLA-DMB;
HLA-DRA; HLA-DOA
class I and class II 11 11 0 up 0.0065 0.0086 HLA-E; HLA-DPA1; HLA-DMA; HLA-DOB;
HLA-DMB; HLA-DRA; HLA-DOA
Pathways were limited to those with R10 but %200 genes. The SAFE analysis utilized 10,000 permutations to establish significance thresholds. CF Relevant
Custom Pathways were developed primarily as described for mice46 using human gene counterparts (Table S8).
aNumber of genes in pathway with increased expression.
bNumber of genes in pathway with decreased expression.
cUp (increased) or down (decreased) differential expression of genes in the pathways associated with milder lung disease. Two-sided indicates pathways that con-
tained both increased and decreased differentially expressed genes that contributed significantly to the signal.
dDetermined by 10,000 permutations in the SAFE package.22
eBenjamini-Hochberg false-discovery for pathways testing within each pathway set; q values < 0.15 were included.
fSee Table S6 (tab C) for the inclusive list of genes for these pathways; see Table S5 for gene MIM numbers.
gFor the two-sided ‘‘Trend,’’ these genes have a ‘‘down’’ trend.
hMetaMiner CF Specific Pathways represent a version of Thomson Reuters’ (formerly GeneGo) MetaDiscovery suite that is enriched with content specific for cystic
fibrosis.proportion of the signal for the P. aeruginosa phenotype
(Figure 1; Table S4). The direction of the association effect
was consistent with the hypothesis that increased expres-
sion of genes in the HLA class II pathways provides protec-
tion against persistent infection with P. aeruginosa early in
life (Table 4). Other pathways exhibiting an ‘‘up’’ signal
included genes involved in endometrial cancer, phospholi-
pase activity, and membrane-bound organelle function/
transport. Pathways associated with MI did not represent
HLA-dominated or endomembrane signatures, but instead
reflected oxidative phosphorylation and overall pointed to
variation in mitochondrial function (Figure 1; Tables S3
and S4).
Genotype and gene expression data were entered into
Matrix eQTL to establish local eQTL associations under
false discovery control.29 SNPs with a minor allele fre-
quency of < 0.01 were removed from the analyses. Expres-
sion quantitative trait loci (eQTLs) were abundant in our
sample set, with a preponderance of significant (q <
0.05) local eQTLs within 1 Mb of the target gene (Table
S7). Many of the genes most strongly associated with the
Consortium lung phenotype also had highly significant
eQTLs (Table S2). To evaluate the hypothesis that differen-
tial expression associated with the Consortium lung
phenotype is at least partially driven by constitutional ge-
netics, rather than treatment or other factors unrelated to
etiology, we performed a global test of concordance for
expression association rank with the lung phenotype
versus eQTL rank, which was highly significant (p ¼
1.253 108). As a further test of this hypothesis, we exam-
ined the heritability values reported in the twin transcrip-
tomic peripheral blood study from the Netherlands Twin
Registry (NTR),30 among the largest eQTL studies yet re-
ported (n¼ 2,752 twins), which obtained estimates of total
additive heritability via a classical twin design. By using a324 The American Journal of Human Genetics 96, 318–328, Februarydescribed permutation approach30 and evaluating genes
expressed in LCLs, we found significant correlation (p ¼
6.43 106) between ranked p values of differential expres-
sion for lung disease severity in our samples. With a multi-
ple regression approach as reported for the NTR heritability
study,30 which corrects for additional genomic factors such
as gene conservation and sequence context (see all factors
considered as predictors in Table 2 of Wright et al.30), the
overlap remained significant (p ¼ 2.9 3 107). We
conclude that heritable factors underlie our differential
expression results, but individual components of the signal
were not strong enough to be identified as significant. The
analogous results for correlation between gene heritability
and differential expression with respect to age of onset of
persistent P. aeruginosa infection or MI, based on a smaller
sample sizes, and GWAS association to lung disease se-
verity, showed no significant overlap with twin heritability
(data not shown).
In summary, this study of gene expression in LCLs from
a large cohort of p.Phe508del homozygotes is one of the
largest clinical expression studies to date and provides
findings complementary to previous CF GWAS results. It
validates the concept that gene expression associated
with biologically and pathophysiologically relevant herita-
ble genomic variation contributes to phenotypic variation
in CF. LPAR6 is the single gene that achieved transcrip-
tome-wide significant association with lung disease.
LPAR6 is a recently described G protein coupled receptor
with no known link to CF; however, LPAR6 is known to
be expressed in pulmonary endothelial cells31 and belongs
to a family of LPA-activated receptors that mediate sig-
naling involved inmultiple biological functions, including
epithelial cell apoptosis, lung fibrosis, and wound heal-
ing.32 Because no SNPs in LPAR6 were even nominally sig-
nificant in previous GWAS analysis,1 epigenetic variation5, 2015
Figure 1. HLA Region Consistently Asso-
ciated with Consortium Lung Phenotype
and Age of Onset of Persistent
P. aeruginosa Phenotype across Multiple
Analyses, but not MI Phenotype
Differential gene expression (left). HLA
class I and II genes (listed on the right
and left sides of each vertical bar, respec-
tively) whose mean expression values are
above the cutoff of expressed genes were
ranked according to the association
strength (t-statistic, negative [; bottom]
or positive [þ; top]; see Table S5 for details)
in the expression data (Consortium lung
phenotype, n ¼ 754; age of onset, n ¼
455; MI, n ¼ 706).
GWAS rank (right). HLA genes represented
in the GWAS panel (n ¼ 1,978) are de-
picted according to strength of association
to Consortium lung phenotype. For GWAS
rank, p values are provided as a reference
to aid interpretation. The width of the
vertical bar represents the relative strength
of the association finding. Individual
genes are color coded for convenience.
GeneSetScan software was utilized to pro-
vide gene ranks for the HLA genes.or complex unrecognized genetic variation (copy-number
variation, insertions/deletions) might be involved at the
LPAR6 locus to explain this finding.
Our most striking discoveries emerged from expression
pathway analysis. Identified pathways, related to the en-
domembrane system for synthesis and post-translational
modification of membrane proteins (membranes, vesicles,
ER/Golgi) and the ER stress response, have been previ-
ously implicated in CF pathophysiology, including
p.Phe508del processing.23,33–35 Although the ER stress
response is related to endomembrane function, the two
signals (post-translational processing and ER stress
response) are both pathologically relevant and are prob-
ably acting independently to modify lung disease pheno-
type. The strength of the genomic signatures in our results
supports continued research directed at these processes
for CF.
The HLA-associated pathways (some overlapping en-
domembrane pathways) point toward antigen processing
and signaling through membrane-bound organelles as
key mediators defining susceptibility to lung disease pro-
gression and bacterial infection. These results support
previous reports implicating HLA alleles in CF-relevant
phenotypes1,36–38 and add to the growing list of disease
phenotypes associated with the major histocompatibility
complex.39 HLA genes have strong eQTL signatures in
various datasets,7,40 including in our own LCL data, and
it is probable that expression and allele type both
interact to define the final functional consequences of
this complex genetic region.41,42 The strong linkageThe Americdisequilibrium across the HLA region suggests that previ-
ously reported HLA allelic associations with phenotypes
should be re-evaluated to consider effects of genetic vari-
ation on gene expression as a mechanistic contributor.
Additionally, the GO pathways annotated to contain
HLA genes are also endomembrane pathways containing
genes previously associated with p.Phe508del processing,
and which probably reflect genetic variation responsible
for producing residual CFTR function as a result of low-
level CFTR processing to the membrane in some CF
individuals.43,44
The use of transformed LCLs for these expression studies
provides an opportunity to rigorously explore gene expres-
sion in a well-characterized CF cohort previously utilized
for GWASs. Given that LCLs are transformed and not
the proximal cell type in the CF lung, their use in this
study has some limitations. Transformation itself can
significantly alter gene expression,45 and genes and path-
ways not expressed in LCLs that would be expressed in
airway cell populations cannot be queried. Nonetheless,
significant gene expression signatures associated with
lung phenotypes were identified. The ability to grow
LCLs in large numbers and under highly controlled culture
conditions are major advantages, and the high power that
was achieved allowed for significant findings to emerge.
The results add to the expanding knowledge supporting
genetic modifier and systems biology studies for CF. Mov-
ing forward, gene expression studies in more proximal
cell types (airway epithelium, freshly isolated cells) should
prove especially powerful. Pathways identified in thisan Journal of Human Genetics 96, 318–328, February 5, 2015 325
study should be considered in on-going and future mech-
anistic studies focused on CF biology.Accession Numbers
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